Number of the records: 1
Preclinical Evaluation of (177)Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor-Overexpressing Tumors
- 1.
SYSNO ASEP 0365501 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Preclinical Evaluation of (177)Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor-Overexpressing Tumors Author(s) Beckford, Denis R. (UJF-V) RID
Eigner, Sebastian (UJF-V) RID
Beran, Miloš (UJF-V)
Eigner-Henke, Kateřina (UJF-V) RID
Lázníček, M. (CZ)
Melichar, František (UJF-V) RID
Chinol, M. (IT)Number of authors 7 Source Title Cancer Biotherapy and Radiopharmaceuticals - ISSN 1084-9785
Roč. 26, č. 3 (2011), s. 287-297Number of pages 11 s. Language eng - English Country US - United States Keywords EGFR ; (177)Lu ; monoclonal antibodies ; Nimotuzumab Subject RIV FR - Pharmacology ; Medidal Chemistry R&D Projects OE08018 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) CEZ AV0Z10480505 - UJF-V (2005-2011) UT WOS 000292447100005 DOI 10.1089/cbr.2010.0916 Annotation Background: The humanized monoclonal antibody Nimotuzumab (h-R3) has demonstrated an exceptional and better clinical profile than other monoclonal antibodies for immunotherapy of epidermal growth factor receptor-overexpressing tumors. This work deals with the preparation and radiolabeling optimization of (177)Lu-Nimotuzumab and their preclinical evaluation. Methods: Nimotuzumab was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), testing different molar ratios. The immunoconjugates were characterized. The radiolabeling with (177)Lu was optimized. Workplace Nuclear Physics Institute Contact Markéta Sommerová, sommerova@ujf.cas.cz, Tel.: 266 173 228 Year of Publishing 2012
Number of the records: 1